David R. Guyer, a former director of EyePoint Pharmaceuticals, Inc., is set to sell 36,975 shares of the company's common stock, with an aggregate market value of $329,817, on October 14, 2024. The shares to be sold were acquired through RSU vesting and stock option exercise on February 9, 2023, and October 14, 2024, respectively. The securities were obtained directly from the issuer as part of compensation and through cash payment. This planned transaction follows the adoption of a trading plan on January 25, 2024. There have been no sales of securities reported in the past three months by Guyer.

David R. Guyer, a former director of EyePoint Pharmaceuticals, Inc., is set to sell 36,975 shares of the company's common stock, with an aggregate market value of $329,817, on October 14, 2024. The shares to be sold were acquired through RSU vesting and stock option exercise on February 9, 2023, and October 14, 2024, respectively. The securities were obtained directly from the issuer as part of compensation and through cash payment. This planned transaction follows the adoption of a trading plan on January 25, 2024. There have been no sales of securities reported in the past three months by Guyer.